加载中
NASDAQHealthcareBiotechnology
最新数据
US$18.1533
−US$0.1467 · -0.80%
Viridian Therapeutics, Inc. is a biotechnology firm committed to creating therapies for patients afflicted by serious illnesses. Its primary development efforts include VRDN-001, a humanized monoclonal anti-IGF-1R antibody currently advancing through Phase 1/2 clinical trials for thyroid eye disease (TED). The company's portfolio also features VRDN-002, an IGF-1R antibody undergoing Phase 1 clinical evaluation, alongside VRDN-003, a therapeutic antibody also designed to target IGF-1R for TED. Established in 2006, this Waltham, Massachusetts-based firm previously operated as Miragen Therapeutics, Inc., before changing its name to Viridian Therapeutics, Inc. in January 2021.
常规交易时段
US$18.11
−US$0.19 · -1.04%
盘中时间采用ET。市场数据可能有所延迟。
Viridian Therapeutics, Inc. is a biotechnology firm committed to creating therapies for patients afflicted by serious illnesses. Its primary development efforts include VRDN-001, a humanized monoclonal anti-IGF-1R antibody currently advancing through Phase 1/2 clinical trials for thyroid eye disease (TED). The company's portfolio also features VRDN-002, an IGF-1R antibody undergoing Phase 1 clinical evaluation, alongside VRDN-003, a therapeutic antibody also designed to target IGF-1R for TED. Established in 2006, this Waltham, Massachusetts-based firm previously operated as Miragen Therapeutics, Inc., before changing its name to Viridian Therapeutics, Inc. in January 2021.
日内区间
当前US$18.11
52周区间
当前US$18.11
盘中时间采用ET。市场数据可能有所延迟。
Viridian Therapeutics, Inc. is a biotechnology firm committed to creating therapies for patients afflicted by serious illnesses. Its primary development efforts include VRDN-001, a humanized monoclonal anti-IGF-1R antibody currently advancing through Phase 1/2 clinical trials for thyroid eye disease (TED). The company's portfolio also features VRDN-002, an IGF-1R antibody undergoing Phase 1 clinical evaluation, alongside VRDN-003, a therapeutic antibody also designed to target IGF-1R for TED. Established in 2006, this Waltham, Massachusetts-based firm previously operated as Miragen Therapeutics, Inc., before changing its name to Viridian Therapeutics, Inc. in January 2021.
日内区间
当前US$18.11
52周区间
当前US$18.11
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 7084.9万 USD | 30.2万 USD | 31.4万 USD | 177.2万 USD | 296.3万 USD |
| 毛利 | 7084.9万 USD | 30.2万 USD | 31.4万 USD | 177.2万 USD | 296.3万 USD |
| 研究与开发 | 3.39亿 USD | 2.38亿 USD | 1.6亿 USD | 1.01亿 USD | 5688.6万 USD |
| 销售、一般及管理费用 | 9531.5万 USD | 6108.3万 USD | 9499.9万 USD | 3518.2万 USD | 2580.5万 USD |
| 营业费用 | 4.34亿 USD | 2.99亿 USD | 2.55亿 USD | 1.36亿 USD | 8269.1万 USD |
| 利息收入 | 2739.9万 USD | 3213.2万 USD | 1856.3万 USD | 491.6万 USD | 31.8万 USD |
| 利息支出 | 494.8万 USD | 304.6万 USD | 184.7万 USD | 48.6万 USD | 3000 USD |
| 折旧和摊销 | 46万 USD | 54万 USD | 52.2万 USD | 25.5万 USD | 12万 USD |
| 营业利润 | −3.63亿 USD | −2.99亿 USD | −2.54亿 USD | −1.34亿 USD | −7972.8万 USD |
| 净利润 | −3.43亿 USD | −2.7亿 USD | −2.38亿 USD | −1.3亿 USD | −7941.3万 USD |
公司数据更新于 2026年10月13日。
已公布业绩及可用的市场共识预期。
已公布业绩及可用的市场共识预期。
第三方分析师预期可能变化，并非 GoAI 建议。
报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI7755.61万0.00%2.3万亿 USD0.03%US$380.84-0.19%
State Street SPDR S&P Biotech ETFXBI4762.86万0.46%103.03亿 USD0.35%US$147.18-2.79%
iShares Russell 2000 ETFIWM4693.8万0.06%787.4亿 USD0.19%US$276.27-0.59%
Vanguard Extended Market ETFVXF2645.97万0.03%954亿 USD0.05%US$231.98-0.66%
iShares Russell 2000 Value ETFIWN1519.36万0.11%137.49亿 USD0.24%US$210.47-0.30%
Dimensional - US Small Cap ETFDFAS1307.19万0.04%338.04亿 USD0.31%US$78.065-0.13%
Vanguard Russell 2000 ETFVTWO1201.85万0.07%180亿 USD0.06%US$111.58-0.62%
Schwab U.S. Small-Cap ETFSCHA1092.22万0.05%217.13亿 USD0.03%US$32.495-0.51%Vanguard Morningstar Total Stock Market ETFVTIState Street SPDR S&P Biotech ETFXBIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Value ETFIWNDimensional - US Small Cap ETFDFASVanguard Russell 2000 ETFVTWOSchwab U.S. Small-Cap ETFSCHAAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
